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fibroblasts is shown to promote tumor
growth.
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Estrogen receptor alpha-positive (ERa+) luminal tu-
mors are themost frequent subtype of breast cancer.
Stat1/mice develop mammary tumors that closely
recapitulate the biological characteristics of this
cancer subtype. To identify transforming events that
contribute to tumorigenesis, we performed whole
genome sequencing of Stat1/ primary mammary
tumors and matched normal tissues. This investiga-
tion identified somatic truncatingmutations affecting
the prolactin receptor (PRLR) in all tumor and no
normal samples. Targeted sequencing confirmed
the presence of these mutations in precancerous
lesions, indicating that this is an early event in tumor-
igenesis. Functional evaluation of these heterozy-
gous mutations in Stat1/ mouse embryonic fibro-
blasts showed that co-expression of truncated and
wild-type PRLR led to aberrant STAT3 and STAT5
activation downstream of the receptor, cellular trans-
formation in vitro, and tumor formation in vivo. In
conclusion, truncating mutations of PRLR promote
tumor growth in a model of human ERa+ breast can-
cer and warrant further investigation.
INTRODUCTION
The transcription factor STAT1 functions as a tumor suppressor
in mammary gland epithelial cells (Chan et al., 2012, 2014;
Schneckenleithner et al., 2011). Selective loss of STAT1 expres-Cell Re
This is an open access article undsion in breast cancer cells is associated with a significant per-
centage of human estrogen receptor alpha-positive (ERa+)
luminal breast tumors (Chan et al., 2012). The lack of STAT1
expression in mice predisposes these animals to mammary
adenocarcinoma development (Chan et al., 2012; Schnecken-
leithner et al., 2011). We demonstrated that spontaneous mam-
mary tumors that develop in Stat1/ female mice progressed in
amanner similar to human ERa+ progesterone receptor-positive
invasive ductal carcinoma (Chan et al., 2012). These tumors also
displayed transcript expression profiles that clustered more
closely with human ERa+ luminal breast cancers than other mu-
rine mammary tumor models and thus recapitulated the molec-
ular characteristics of the luminal breast tumor subtype (Chan
et al., 2012; Pfefferle et al., 2013).
To further identify the biological consequences of STAT1 loss
in ERa+ luminal breast cancer, we set out to uncover genomic
event(s) that fully transform the phenotype of mammary gland
epithelial cells into cancer cells in the Stat1/ mouse model.
We performed whole genome sequencing of 14 primary
Stat1/ mammary tumors, 5 primary Stat1/ ovarian hor-
mone-independent tumors, and 3 Stat1/ tumor-derived cell
lines for a total of 22 independent Stat1/ tumors (Figure 1).
We compared genomic variations in tumor samples with those
in control samples that consisted of 10 wild-type, 5 tumor-free
Stat1/mammary glands, and 15Stat1/ tails. Our analysis re-
vealed relatively few copy number variation (CNV) events in pri-
mary Stat1/ mammary tumors and a point mutation rate
consistent with that observed in human breast cancers. A num-
ber of key genes reported in human cohorts were alsomutated in
the Stat1/ mammary tumors including Trp53, Brca1, andMll3
and theArid family. Strikingly, we identified a truncatingmutation
hotspot within the prolactin receptor (Prlr), with mutationsports 17, 249–260, September 27, 2016 ª 2016 The Author(s). 249
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Figure 1. Sample Summary
Samples from wild-type 129/Sv (+/+) and Stat1 knockout (/) mice were used for discovery whole-genome sequencing and subsequent extension sequencing
targeting Prlr. Mice with matched normal tail DNA used for analysis are indicated with a red tail. Ductal carcinoma in situ (DCIS) samples were prepared from
formalin-fixed, paraffin embedded (FFPE) samples. See also Table S7 and Figure S2.affecting 100% of the Stat1/ mammary tumor samples and
0% of control samples examined. Co-expression of full-length
and truncated PRLR in immortalized Stat1/ mouse embryonic
fibroblasts (MEFs) led to activation of the downstream onco-
genic substrates STAT3 and STAT5, transformation of MEFs
in vitro, and tumor formation in mice.
RESULTS
Summary of Somatic Alterations
In a discovery set of 22 Stat1/ tumor samples, using whole
genome sequencing (WGS), we detected over 10,112 single
nucleotide variants (SNVs) and 3,331 insertions and deletions (in-
dels) within or near coding regions of known genes. Filtering and
manual review reduced the set to 1,770 SNVs and 88 indels (Ta-
ble S1). The 1,858 mutations occurred in 1,649 genes with 139
recurrently mutated genes (occurring in two or more samples)
across all 22 tumors (Table 1 and Table S2). Mutational signifi-250 Cell Reports 17, 249–260, September 27, 2016cance analysis revealed 16 significantly mutated genes (false
discovery rate [FDR] < 0.05, likelihood ratio test [LRT] method;
Table S3) (Dees et al., 2012). The most recurrently and signifi-
cantly mutated gene was the prolactin receptor (Prlr), found in
17 out of 22 samples. These Prlr mutations will be discussed in
greater detail below. Beyond the Prlr gene, mutations were
observed in many of the same key genes and pathways reported
previously for human breast and ovarian cancer, including
Trp53, DNA repair genes (Brca1, Rad50, Rfc2, Poln, and Polr2a),
chromatin modifiers (Arid1a and Arid1b), transcription factors
(Zfp335, Zfp523, Zfp119a, Zfp119b), and kinases and phospha-
tases (Ptprb, Pik3r2, Pik3cd, Mapk7, and Src) (Banerji et al.,
2012; Cancer Genome Atlas Network, 2012; Ellis et al., 2012;
Jones et al., 2010; Stephens et al., 2012; Wiegand et al., 2010).
Other mutations of note were in Ip6k2, which encodes a protein
that affects the growth suppressive and apoptotic activities of
interferon-beta in ovarian cancers (Morrison et al., 2001);
Tiam1, which is a t-lymphoma invasion and metastasis-inducing
Table 1. Recurrently Mutated Genes with Mutations in More
Than Two Tumors from WGS
Gene Common Name Mutations (n) Samples (n)
HGNC
Symbol
Prlr* 17& 17& PRLR
Olfr1062* 5 5 N/A
Mll3 4 4 MLL3
4932431P20Rik* 4 4 WDR87
Gm10750 4 4 N/A
Gatsl3 3 3 GATSL3
Gnl1* 3 3 GNL1
Esrrg* 3 3 ESRRG
Galnt5* 3 3 GALNT5
BC006779 3 3 N/A
Rbbp6 3 3 RBBP6
Slc39a12* 3 3 SLC39A12
Zfp335 3 3 ZNF335
Gm6369 3 3 N/A
Fbxl7 4 3 FBXL7
Krt15* 3 3 KRT15
Tgoln1* 3 3 TGOLN2
Gm16372 3 3 N/A
Trp53* 3 3 TP53
Taar7e* 3 3 N/A
4930503E14Rik* 3 3 N/A
ENSMUSG00000077055 3 3 N/A
Tmem181b-ps 3 3 TMEM181
Gm10601 3 3 N/A
A230087F16Rik 3 3 N/A
Gm11867 3 3 N/A
Gm16957 3 3 N/A
Vmn2r90 3 3 N/A
Mutations, total number of mutations identified; samples, number of
samples with at least one mutation. Multiple mutations within the same
gene per sample are possible. &Prlrmutations were called in 17/22 tumor
samples during initial calling from WGS data. Manual review and subse-
quent validation assays confirmed mutations in 22/22 tumor samples.
*Significantly mutated genes (Table S3). See also Table S1, Table S2,
and Table S3.protein; and Esrrg, which encodes the estrogen-related receptor
gamma protein. No significant differences were observed in
mutation frequencies between ovarian dependent and indepen-
dent tumors or cell lines, although we are admittedly underpow-
ered to detect such differences.
The numbers of mouse whole genomes sequenced in our
study (n = 22) limit the direct comparison of mutation fre-
quencies. Despite this, we compared our cohort to mutations
frequently observed in human luminal breast cancers by identi-
fying genes mutated at >5% frequency in The Cancer Genome
Atlas (TCGA) luminal A and B cohort (n = 699) (Cancer Genome
Atlas Network, 2012). We observed Trp53 and Mll3 mutations
at frequencies comparable to the human dataset with 14%
versus 16% and 18% versus 8%, respectively (Figure S1). Thelack of Pik3ca and Map3k1 mutations is perhaps expected in
the context of PRLR truncation (see below) given that their activ-
ity is downstream of PRLR and, therefore, activatingmutations in
these genes may not be required for tumor formation.Gata3mu-
tations were also not observed in our dataset, although we pre-
viously showed upregulation of Gata3 in Stat1/ tumors,
consistent with ERa+ human breast cancer (Chan et al., 2012).
Summary of Copy Number Variation Results
As a positive control, in each tumor we verified that the Stat1
exon 3–5 deletion was detectable by read-depth-based CNV
analysis using CopyCat. Only moderate additional copy number
changes were observed in tumor samples (Table S9). Virtually no
CNV events were observed in wild-type or Stat1/ tumor-free
mammary glands (Table S9).
Recurrent Truncating Mutations of PRLR
As described above, the most recurrently mutated gene in
Stat1/ mammary tumors was that of prolactin receptor (Prlr)
(Table 1). Prlr mutations were not observed in any matched
normal tails (0/17), wild-type mammary glands (0/10), or tumor-
free Stat1/ mammary glands (0/5). Our alignment and variant
calling pipelines and further manual inspection of WGS data for
the Prlr region revealed Prlr mutations in a total of 21/22 tumors
(Table 2; Appendix S1). Only the TAC246 tumor sample had no
evidence of a Prlr mutation in the initial discovery WGS dataset.
All discovery tumor samples were further Sanger sequenced for
the Prlr region of interest to validate the observed indels (Table
S4; Appendix S2). Sequence traces consistent with the WGS
mutations were confirmed for 19 of 21 tumors. Traces for two
samples were ambiguous. However, detection of indels from
Sanger traces is difficult and this, in our experience, represents
a very high indel validation rate. MiSeq sequencing of a
formalin-fixed paraffin-embedded (FFPE) sample from the
TAC246 tumor identified a Prlr mutation in this sample that was
missed in the original discovery set by WGS (giving a sensitivity
of 95.5% for the 30X WGS approach of detecting Prlr muta-
tions). A second mutation was additionally detected by MiSeq
data of an FFPE sample from the TAC247 tumor that was also
missed byWGS. As a result, 100%of the original discovery sam-
ples were found to contain at least one Prlrmutation (Figure S2).
Extension sequencing, by the Sanger method, was performed
on an additional 10 tumors and 35 non-tumor samples from 10
additional mice (Appendix S3). Non-tumor samples included
10 normal tails, 8 uteri, 7 ovaries, 8 livers, and 2 mammary
glands. Prlr mutations were observed in all additional tumors
and none of the non-tumor samples (Figure S2).
In order to determine whether Prlr mutations are an early tu-
mor-initiating event, ductal carcinoma in situ (DCIS) components
were identified from FFPE blocks of additional Stat1/ mam-
mary glands. DCIS DNA samples were amplified for the mutated
Prlr region and sequenced by MiSeq (Appendix S4). In total,
seven of nine (77.8%) DCIS samples showed evidence of trun-
cating Prlr mutations. Immunohistochemical analysis also indi-
cated that activated STAT3 and STAT5 were present in a major-
ity of the atypical cells in DCIS (Figure S3), which was consistent
with our previous results for pSTAT3/5 in primary Stat1/ tu-
mors (Chan et al., 2014). These results suggest that mutationsCell Reports 17, 249–260, September 27, 2016 251
Table 2. Summary of Prlr Mutations in Discovery and Extension Sets
Start Stop Variant Sample Variant Effect
AA
Change Set WGS
PCR
Sanger
PCR
MiSeq
10258182 10258182 G/0 B3R15 L. tho. frame_shift_del p.G330fs discovery Y Y N/A
10258180 10258180 C/0 B3R1R2L1 R. tho. frame_shift_del p.P329fs discovery Y Y N/A
10258151 10258151 G/0 OVX3L2 R. tho.a frame_shift_del p.L320fs discovery Y Y N/A
10258151 10258151 G/0 OVX6R2 L. cerv.a frame_shift_del p.L320fs discovery Y Y N/A
10258147 10258147 G/0 SSM1 frame_shift_del p.E318fs discovery Y Y N/A
10258139 10258140 0/TGAGGACGAGC SSM2 frame_shift_ins p.E319fs discovery Y Y N/A
10258195 10258195 A/0 SSM3 frame_shift_del p.K334fs discovery Y Y N/A
10258180 10258180 C/0 TAC171 R. tho.a frame_shift_del p.P329fs discovery Y Y N/A
10258147 10258147 G/0 TAC183 R. tho.a frame_shift_del p.E318fs discovery Y Y N/A
10258147 10258148 0/GATGGCT TAC186 L. cerv.a frame_shift_ins p.E318fs discovery Y Y N/A
10258178 10258186 ATCCGGGTC/0 TAC246 R. ing. in_frame_del p.Y328* discovery N N Y
10258147 10258147 G/0 TAC247 L. cerv. frame_shift_del p.E318fs discovery N N Y
10258153 10258168 CTAATGCCATCCCATT/0 TAC247 L. cerv. frame_shift_del p.L320fs discovery Y A Y
10258182 10258182 G/0 TAC266 L. tho. frame_shift_del p.G330fs discovery Y Y N/A
10258151 10258154 GGCT/0 TAC268 L. tho. frame_shift_del p.R319fs discovery Y Y N/A
10258147 10258147 G/0 TAC269 L. cerv. frame_shift_del p.E318fs discovery Y Y N/A
10258180 10258180 C/0 TAC270 L. cerv. frame_shift_del p.P329fs discovery Y Y N/A
10258147 10258148 GA/0 TAC270 L. ing. frame_shift_del p.E318fs discovery Y Y N/A
10258179 10258179 T/A TAC271 R. tho. nonsense p.Y328* discovery Y A N/A
10258146 10258168 CGAGCGGCTAATGCCAT
CCCATT/0
TAC272 L. tho. frame_shift_del p.E318fs discovery Y Y N/A
10258195 10258195 A/0 TAC273 L. tho. frame_shift_del p.K334fs discovery Y Y N/A
10258146 10258149 CGAG/0 TAC273 R. ing. frame_shift_del p.E318fs discovery Y Y N/A
10258147 10258147 G/T TAC274 R. ing. nonsense p.E318* discovery Y Y N/A
10258184 10258184 G/0 OVX13R1R2 L. ing.a frame_shift_del p.G330fs extension N/A Y N/A
10258181 10258181 C/0 TAC297 L. tho. frame_shift_del p.P329fs extension N/A Y N/A
10258148 10258149 AG/0 TAC298 L. tho. frame_shift_del p.E318fs extension N/A Y N/A
10258147 10258147 G/T TAC299 R. tho. nonsense p.E318* extension N/A Y N/A
10258181 10258181 C/0 TAC300 L. tho. frame_shift_del p.P329fs extension N/A Y N/A
10258194 10258194 T/0 TAC300 R. ing. frame_shift_del p.K334fs extension N/A Y N/A
10258151 10258169 GGCTAATGCCATCCCA
TTC/0
TAC301 L. tho. frame_shift_del p.R319fs extension N/A Y N/A
10258142 10258149 AGGACGAG/0 TAC302 R. cerv. frame_shift_del p.E316fs extension N/A Y N/A
10258184 10258184 G/0 TAC311 L. cerv. frame_shift_del p.G330fs extension N/A Y N/A
10258147 10258147 G/T TAC311 L. ing. nonsense p.E318* extension N/A Y N/A
10258222 10258223 0/A TAC299 L. tho. frame_shift_ins p.D343fs DCIS N/A N/A Y
10258151 10258173 GGCTAATGCCATCCCAT
TCCAAA/-
TAC312 L. tho. frame_shift_del p.L320fs DCIS N/A N/A Y
10258177 10258177 T/- TAC314 L. tho. frame_shift_del p.Y328fs DCIS N/A N/A Y
10258151 10258173 GGCTAATGCCATCCCAT
TCCAAA/-
TAC319 L. ing. frame_shift_del p.L320fs DCIS N/A N/A Y
10258147 10258147 G/- TAC319 R. ing. frame_shift_del p.E318fs DCIS N/A N/A Y
10258154 10258191 TAATGCCATCCCATTCCAAA
GAGTATCCGGGTCAAGGT/-
TAC322 L. tho. frame_shift_del p.L320fs DCIS N/A N/A Y
10258147 10258147 G/- TAC323 L. tho. frame_shift_del p.E318fs DCIS N/A N/A Y
Coordinates for thePrlr gene (Ensembl: ENSMUST00000124470; v67;mm9) are for chromosome 15. Abbreviations:WGS, whole genome sequencing;
Y, mutation observed; N, mutation not observed; N/A, mutation data not available for technology; A, mutation calling ambiguous; L. tho., left thoracic;
R. tho., right thoracic; L. cerv., left cervical; R. ing., right inguinal; L. ing., left inguinal; R. cerv., right cervical. A mutation for ‘‘TAC246 R. ing’’ was not
observed inWGS or PCR Sanger assay but was observed by the PCRMiSeqmethod. See also Table S4, Table S5, Table S10, Appendix S1, Appendix
S2, Appendix S3, and Appendix S4.
aOvarian-hormone independent tumor.
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Figure 2. Mutational Hotspot Analysis
of Prlr
The diagrams depict the full-length, 608 amino
acid residue coding region of Prlr (Ensembl:
ENSMUST00000124470; v67) that is encoded by
9,900 base pairs. (A) depicts mutations identified
in the original discovery set of tumors by whole
genome sequencing and (B) depicts those identi-
fied in the extension/validation set (including DCIS
samples) by Sanger/MiSeq sequencing. A total of
32 frame-shift deletions, 3 frame-shift insertions, 4
nonsense SNVs, and 1 in-frame deletion intro-
ducing a stop codon were identified in Prlr that
cluster in 2 hotspots around residues 318 and 330.
See also Figure S4, Table S5, Table S10, Appendix
S1, Appendix S2, Appendix S3, and Appendix S4.in Prlr and activation of the PRLR pathway are early events dur-
ing tumorigenesis of Stat1/ mammary epithelial cells.
The final set of 40 Prlrmutations observed included 32 frame-
shift-deletions, 3 frame-shift-insertions, 4 non-sense SNVs, and
1 in-frame deletion introducing a stop-gain (Table 2 and Table
S5; Figure 2). All mutations were located within an 85 base pair
window (chr15:10258139–10258223) of the mouse reference
genome (build mm9). These mutations are predicted to produce
a truncated PRLR protein only 317 to 349 amino acids (aa) in
length compared to the 608 aa full-length wild-type PRLR
(Figure S4). The truncated forms result in loss of most, but not
all, of the PRLR cytoplasmic tail. They share the first 285 aa
with the known ‘‘S1b’’ short-form with 32 to 64 additional amino
acids and total lengths ranging between the ‘‘S1c’’ and ‘‘S1a’’
forms (Bole-Feysot et al., 1998; Pujianto et al., 2010). Examina-
tion of WGS data showed that nearly all Prlr mutations, except
for the SSM1 tumor cell line, appeared to be heterozygous.
Although definitive determination of zygosity from Sanger and
MiSeq data was challenging, especially for FFPE samples, we
did not find any additional samples in the extension set that
were obviously homozygous for the truncation mutation. To
identify germline variants that may produce a similar effect, we
searched the Sanger Mouse Sequencing Project (version 5)
(Keane et al., 2011; Yalcin et al., 2011) and identified a single
missense variant (dbSNP: rs46169444) and no indels within
this hotspot region.Cell RepFunctional Significance of the
Truncated Form of PRLR Protein
Because all but one of the observed Prlr
mutations in primary Stat1/ mammary
tumors occurred in one of two alleles
and all of the primary tumors examined
so far displayed constitutive PRLR
pathway activation, we hypothesized
that heterodimers of full-length (FL) and
truncated (T) PRLR may be the cause
of constitutive PRLR activation and,
thus, the tumorigenic phenotype of
the Stat1/ mammary epithelial cells.
Endogenous expression of the FL and T
PRLR isoforms was verified in Stat1/mammary tumor cell lines harboring these mutations (SSM1,
SSM2, and SSM3) by immunoprecipitation and western blotting
(Figure S5A). In contrast to the SSM2 and SSM3 tumor cell lines,
which are heterozygous for the mutation, the SSM1 tumor cell
line was homozygous (Table 2; Figure S5A) and failed to display
constitutive PRLR-JAK2-STAT3/5 signaling (Chan et al., 2014).
To directly examine the activity of the two PRLR isoforms, FL
or T PRLR (aa residues 1 to 317) were expressed either alone
or together in non-transformed Stat1/murine embryonic fibro-
blasts (MEFs). Expression of the PRLR isoforms was confirmed
by flow cytometry using a PRLR-specific monoclonal antibody
(Figure S5B) (Chan et al., 2014). In the absence of exogenous
PRL stimulation, phosphorylation of STAT3 and STAT5 was
detected in cells expressing both FL and T PRLR, but not in cells
expressing either FL PRLR homodimers or T PRLR homodimers
alone (Figure 3A). Therefore, co-expression of FL and T PRLR led
to phosphorylation and activation of STAT3 and STAT5 in the
absence of exogenous PRL stimulation.
To further determine the biological significance of FL and T
PRLR heterodimers, Stat1/ MEFs expressing both FL and T
PRLR were analyzed for their ability to grow in an anchorage-in-
dependent manner. Cells expressing FL and T PRLR developed
significantly more colonies than control MEFs (p = 0.0013), or
those expressing FL alone (p = 0.0013) or T alone (p = 0.0015),
when plated in soft agar (Figures 3B and S5C). Stat1/ MEFs
expressing both FL and T PRLR also developed significantlyorts 17, 249–260, September 27, 2016 253
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Figure 3. Co-expression of Full-Length and
Truncated PRLR Promote STAT3 and
STAT5 Activation, Cellular Transformation
In Vitro, and Tumor Formation In Vivo
(A) Stat1/ MEFs expressing full-length (FL),
truncated (T) PRLR, or both (FL/T) were stained for
phosphorylated STAT3 (pSTAT3) or phosphory-
lated STAT5 (pSTAT5) (y axis). Rabbit (Rb) IgGwas
used as an isotype control. MEFs also expressed
mJAK.IRES.GFP (x axis) to mediate signaling
downstream of the PRLR proteins.
(B) Stat1/ MEFs expressing the indicated
PRLR constructs were analyzed by anchorage-
independent soft agar assay. The number of col-
onies was counted after single cells had been
cultured for 3 weeks. Error bars represent SEM.
(C) Stat1/ MEFs alone (-), Stat1/ MEFs
transduced with vector alone (JAK2), or vector
expressing full-length (FL/FL-JAK2), truncated
(T/T-JAK2), or both (FL/T-JAK2) PRLR were im-
planted into nude mice. Stat1/ MEFs ex-
pressing KRAS were used as positive control.
Tumor growth was monitored over time. The per-
centages of animals that developed palpable tu-
mors in each experimental group were plotted.
*p < 0.05, **p < 0.002, ***p < 0.0001. See also
Figure S3 and Figure S5.more tumors in nude mice than MEFs expressing vector alone
(p = 4.867E5), FL PRLR alone (p = 0.0344), or T PRLR alone
(p = 3.365E4) (Figure 3C). Tumor formation occurred more
quickly in mice that received FL/T expressing MEFs than FL
alone (p = 0.0002), T alone (p = 0.0003), vector alone (p =
0.0002), orMEFs alone (p < 0.0001; Figure S5D). FL/T expressing
MEFs formed tumors at a frequency similar to the KRAS ex-
pressing positive control (p = 0.238), although at a significantly
slower rate (p < 0.0001). Taken together, these results indicate
that FL/T PRLR heterodimers promote activation of oncogenic
STAT3 and STAT5, anchorage-independent growth, and trans-
formation of non-transformed Stat1/ MEFs.
PRLR Mutations and Isoform Usage in Human Breast
Cancers
To assess the prevalence of PRLR mutations in human breast
cancers, we examined human breast cancer exome sequence
data from 991 patients made publicly available through the
TCGA data portal. Using the published MAF file, four mutations
in PRLR, including two SNVs and two indels, were identified
(Cancer Genome Atlas Network, 2012). One of these mutations,
an indel (L360fs), causes a truncating mutation in the human
PRLR exon 10 (Ensembl: ENST00000382002; v70_37), analo-254 Cell Reports 17, 249–260, September 27, 2016gous to that observed in the mouse
Stat1/ mammary tumors. Manual re-
view of alignment data for this exon iden-
tified four additional truncating indels at
E313fs (2/47 reads), L315fs (2/44),
L360fs (35/42), and K460fs (3/100) from
samples TCGA-B6-A0X7, TCGA-A2-
A04R, TCGA-AC-A3EH, and TCGA-AR-
A5QQ, respectively. L360fs, E313fs, andL315fs were found in luminal subtype breast cancers, whereas
K460fs was in a basal breast cancer. The Exome Aggregation
Consortium (ExAC) reports only four individuals with rare (allele
frequency < 0.00001) germline truncating mutations in PRLR at
A597fs, N568fs, S27*, and W180* (Lek et al., 2016).
There are currently eight to ten reported complete protein-
coding transcript isoforms for human PRLR according to En-
sembl: ENSG00000113494 (v79), University of California, Santa
Cruz (UCSC) Genome Browser database: PRLR (GRCh37/
hg19), and UniProt: P16471 (v175) that can be broadly grouped
as long, intermediate, and short PRLR isoforms (Bole-Feysot
et al., 1998) (Figure S6; Table S6). We investigated the possibility
of an increase in the expression of truncated (i.e., short) PRLR
relative to full-length (i.e., long) PRLR in human ERa+ luminal
breast cancer. We hypothesized that a skewing toward more T
PRLR expression could be functionally equivalent to PRLR trun-
cation. The expression ratio of FL to T PRLR was calculated
using the TCGA human breast RNA sequencing (RNA-seq) data-
sets based on counts for isoform-specific junctions (see Exper-
imental Procedures). We also analyzed the STAT1 expression
status of human luminal and basal or Her2 breast cancers and
stratified each tumor subtype into STAT1-low and STAT1-high.
In a previous report, we demonstrated that STAT1 was
Figure 4. PRLR Isoform Usage versus STAT1 Expression in Human TCGA Breast Cancer RNA-Seq Data
STAT1 expression levels from TCGA RNA-seq data were binned into tertiles (low, medium, high) (mid panels) and separated into luminal and basal or Her2 breast
cancer subtypes. The ratios of full-length (FL) to truncated (T) PRLR isoform expression (FL/T ratio values) calculated in terms of junction per million (JPM) were
compared using a Wilcoxon rank sum test with continuity correction between low and high STAT1 expressing groups (top panels). For reference, read counts of
FL and T are plotted (bottom panels). See also Figure S6 and Table S6.specifically downregulated in tumor cells, but not in stromal
cells, in ERa+ luminal breast cancers (Chan et al., 2012).
Although the human breast tumor TCGA RNA-seq datasets
were generated from whole tumors, we observed an overall sig-
nificant reduction in the STAT1 expression level in the luminal
breast cancer subtype compared to basal and Her2 subtypes
(p = 2.484E06), reflecting the selective downregulation of
STAT1 in these tumor cells, which was consistent with our previ-
ous report (Chan et al., 2012). We then analyzed the FL/T PRLR
ratio in STAT1-low and STAT1-high tumors among each sub-
type. We observed a significant increase in T PRLR expression
relative to FL PRLR expression (i.e., lower FL/T ratio) in STAT1-
low samples compared to STAT1-high samples among luminalsubtype tumors (p = 0.0077; Figure 4). No significant difference
in FL/T ratio was observed among the basal or Her2 breast tumor
group (p = 0.723). These data indicate that there may be a pref-
erential usage of the truncated PRLR isoform in tumor cells with
reducedSTAT1 expression among ERa+ luminal breast cancers.
DISCUSSION
In this study, we identified recurrent gene mutations that were
associated with the tumorigenic landscape of ERa+ Stat1/
luminal mammary gland tumors. Several of these genes have
also been reported as significantly mutated in human breast can-
cers, underscoring the biological significance of these mutationsCell Reports 17, 249–260, September 27, 2016 255
in the pathogenesis of this disease. Our study also revealed a po-
tential mechanism whereby ERa+ luminal breast cancer initiates
and progresses. Loss of Stat1 expression in mammary cells fa-
vors acquisition of mutations in an 85 base-pair hotspot of
exon 10 of the Prlr gene (Ensembl: ENSMUST00000124470;
v67), resulting in a truncation of the cytoplasmic tail of the prolac-
tin receptor (PRLR). Concurrent expression of full-length and
truncated PRLR in the absence of STAT1 promotes phosphory-
lation and activation of the oncogenic STAT3 and STAT5,
anchorage-independent growth of mouse embryonic fibro-
blasts, and tumor formation in nude mice.
PRLR is a transmembrane homodimeric receptor with an
extracellular region that binds prolactin (PRL). It functions as a
cytokine receptor and activates second messenger cascades,
including the JAK2-STAT3/5, JAK-RUSH, RAS-RAF-MAPK,
and PI3K pathways (Aksamitiene et al., 2011; Helmer et al.,
2010; Rui et al., 1994). Over 75% of human ERa+ breast cancers
display persistent PRLR-JAK2-STAT3/5 signaling (Chan et al.,
2014). Activation of PRLR-JAK2-STAT3/5 signaling has been
implicated in the upregulation of steroid hormone receptor
expression and malignant progression of breast cancer (Chan
et al., 2014; Fiorillo et al., 2013). There is also support for an as-
sociation between PRLR allelic variations and breast cancer risk
(Bogorad et al., 2008; Lee et al., 2007; Mong et al., 2011; Vacla-
vicek et al., 2006). In lobular neoplasia, amplification of PRLR
may also be important for pathogenesis and progression (Tran-
Thanh et al., 2011). Additionally, mouse mammary cancer
models support a role for PRLR signaling in tumor progression.
Elevated production of PRL ligand, driven by the Neu promoter,
causes development of carcinomas in mice resembling human
luminal breast carcinomas (Arendt et al., 2011). We have also
shown that loss of STAT1 expression results in unopposed
PRLR signaling, promotes expansion of mammary luminal pro-
genitor cells, and leads to development of ductal carcinoma
in situ (DCIS) and, finally, invasive mammary carcinomas (Chan
et al., 2014). Lack of PRLR signaling has the opposite effect,
whereby PRLR-deficiency delays tumor onset in the C3(1)
SV40T model of mammary cancer (Oakes et al., 2007). Similarly,
pharmacological inhibition of JAK2 (BMS-911543) not only abro-
gates mammary tumor formation but also causes regression
of established Stat1/ mammary tumors, demonstrating that
constitutive activation of the PRLR-JAK2-STAT3/5 pathway pro-
motes tumor progression and maintenance (Chan et al., 2014).
Therefore, there is strong evidence supporting the involvement
of PRLR signaling in the pathogenesis of ERa+ breast cancer.
Themechanismbywhich thePRLRpathway is activatedduring
the development of ERa+ breast cancer is, however, less clear.
Although elevated serum PRL levels have been associated with
increased risk of developing ERa+ breast cancer (Tworoger
et al., 2015), it has been difficult to definitively show a causal rela-
tionship between PRLR pathway activation and breast cancer
progression in those individuals who exhibited high PRL levels
prior to diagnosis. In a recent study by Tworoger and colleagues,
half of the patients with ERa+ breast cancer did not show high
plasmaPRL levels when blood samples were collected <10 years
prior to diagnosis (Tworoger et al., 2013), suggesting that the as-
sociationofPRLRsignaling anddevelopmentofERa+breast can-
cer may be more complex than simply elevated PRL production.256 Cell Reports 17, 249–260, September 27, 2016In our previous report, we showed that excess production of
PRL ligand was not the cause of constitutive activation of PRLR-
JAK2-STAT3/5 signaling in Stat1/ mammary tumors (Chan
et al., 2014). In this study, we sought to identify a mechanism
whereby constitutive oncogenic PRLR signaling was established
andmaintained in the absenceof aberrant overproduction ofPRL.
We showed that heterodimers consisting of full-length and trun-
catedPRLR activate JAK2-STAT3/5 in the absence of exogenous
PRL stimulation. PRLR truncation and STAT3/5 activation were
also observed in DCIS in Stat1/ mammary glands, indicating
that persistent PRLR signaling mediated by PRLR mutations
was an early tumorigenic event. These results suggest that FL/T
PRLR heterodimers could contribute to ERa+ breast cancer
development inpatientswith normal PRL levelsdue to the intrinsic
ability of the heterodimers to signal without ligand stimulation.
Because this observation wasmade inmice and cell lines without
STAT1 expression, it is likely that the ability of the heterodimers to
confera tumorigenic effectwouldbecorrelatedwith the lossof the
negative regulator that normally controls PRLR signaling.We pre-
viously showed that approximately half of ERa+ luminal breast
cancers displayed selective downregulation of STAT1 expression
in tumor cells (Chan et al., 2012). Given that the STAT1-SOCS1
pathway negatively regulates PRLR signaling (Chan et al., 2014),
it would be interesting to determine whether breast cancer cells
in patients with normal PRL levels have down-modulated STAT1
and/or SOCS1 expression. Our study also indicated that trun-
cated PRLR homodimers alone failed to transform Stat1/
MEFs or promote tumor formation in mice (Figure 3). This is
consistent with the finding that truncated PRLR lacks the STAT5
binding sites at residues 496 and 597 (Figures 2 and S4) and
that STAT5 activation is necessary for transformation. Full-length
homodimers also failed to transform Stat1/ MEFs in vitro and
showed significantly reduced oncogenic activity in vivo. There-
fore, it seems that co-expression of FL and T PRLR is required
to collaborate with STAT1 loss and promote tumor progression.
One might expect that PRL-mediated tumor induction in the
case of the NRL-PRL transgenic model (Arendt et al., 2011)
and constitutive PRLR pathway activation in the case of
Stat1/ tumors (Chan et al., 2014) would lead to similar patho-
logical outcomes. However, the tumors developed in Stat1/
mice were mechanistically different from the tumors developed
in NRL-PRL transgenic mice reported by Arendt and colleagues
(Arendt et al., 2011; Chan et al., 2014). Arendt et al. (2011)
found that PRL-inducedmousemammary carcinomas were het-
erogeneous with respect to histology, ER/PR expression, and
signaling cascades (e.g., STAT5 signaling) and were insensitive
to ER-mediated signaling. Our model is less heterogeneous, in-
dependent of over-production of PRL ligand, and sensitive to
ER-mediated signaling. In addition, although JAK2 is required
for initiation of the NRL-PRL tumors, it is not essential for tumor
maintenance. In contrast, Stat1/ tumors require JAK2 activa-
tion for both initiation and progression. Although the tumor-initi-
ating cell population in the Stat1/ tumors is the luminal progen-
itor subtype (Chan et al., 2014), it is not clear from which specific
cell compartment the NRL-PRL tumors are derived. Given the
distinct mode of tumorigenesis, the potential difference in tar-
geted tumor-initiating cell populations, and the presence of
STAT1 in the NRL-PRL model, it is likely that these differences
might explain the different endocrine sensitivity and biological
outcome of the two models.
We observed 4 PRLR truncating mutations in human breast
cancer TCGA datasets. To our knowledge, only 2 exome
sequencing studies of DCIS have been published, with 11 and
9 cases, respectively, and neither reports any PRLR mutations
(Banerji et al., 2012; Kim et al., 2015). It is possible that PRLR
truncation may occur as other types of genomic alterations,
such as larger scale deletions, gene fusions, or translocations
that are not easily detected from TCGA exome or RNA-seq
data. More detailed structural analyses of breast cancer ge-
nomes will be required to further explore this possibility.
Changes in the expression of naturally occurring alternative tran-
script isoforms may also provide a mechanism of PRLR deregu-
lation. The human S1a and S1b truncated PRLR isoforms are
generated by alternative splicing. Their roles in the development
of ERa+ breast cancer remain to be clarified. Dufau and col-
leagues reported an increase in mRNA expression of the full-
length PRLR over the short S1a and S1b PRLR isoforms in hu-
man breast cancers (Meng et al., 2004). Our analyses compared
all of the known short isoforms (S1a, S1b, D4 S1b, DS4-D7/11,
D7/11, DS1) to the full-length isoform and observed a significant
increase in expression of the short isoforms over full-length
PRLR in STAT1-low luminal, but not basal breast cancer.
Because tumor subtypes of the datasets used in the Dufau study
were not classified, it was difficult to directly compare their
results to our current study.
The biological significance of the PRLR short isoforms has
been controversial. Some studies indicate that the PRLR short
isoforms act as dominant negatives and block signaling from
full-length PRLR (Hu et al., 2001). However, expression of the
PRLR short isoform alone is sufficient to rescue the mammary
gland differentiation defect in Prlr+/ mice (Binart et al., 2003),
indicating that PRLR short isoform is not a dominant negative
and FL PRLR and PRLR short isoform heterodimers can indeed
transduce signals. None of these past studies examined the
ability of the FL PRLR and PRLR short isoform heterodimers to
transform normal cells. We demonstrate the ability of these
heterodimers to transform mouse embryonic fibroblasts and
promote tumor formation in nude mice. This model also recapit-
ulated the pSTAT3/5 activation we observed in primary tumors
and DCIS samples. However, these experiments were per-
formed using MEFs rather than the primary cell of origin, and
future studies should assess the tumorigenic property of PRLR
heterodimers in Stat1/ mammary epithelial cells (MECs) with
endogenous levels of JAK2. We speculate that the truncated
PRLR short form is able to prolong signaling in the absence of
PRL ligand because of its increased half-life on the cell surface.
Phosphorylation of Ser349 on PRLR recruits the beta-transducin
repeats-containing protein (b-TrCP) ubiquitin-protein ligase (Li
et al., 2006). This interaction is important for ubiquitin-dependent
degradation of the PRLR to terminate signaling. The truncated
PRLR described in our current study lacks this critical serine res-
idue, suggesting that it may be insensitive to b-TrCP-mediated
degradation. Consistent with this hypothesis, phosphorylation
on Ser349 is diminished in human breast cancer cell lines, lead-
ing to an increase in PRLR expression levels (Li et al., 2006).
In addition, although FL PRLR and the truncated S1b isoformhave similar binding affinity to growth hormone, the level of spe-
cific binding by S1b is significantly higher than that of FL PRLR
on COS-1 or HEK293 cells transfected with either isoform (Hu
et al., 2001; Trott et al., 2003). These results suggest that the
cell surface expression of S1b PRLR is elevated compared to
that of FL PRLR. Therefore, it is conceivable that increased FL/
T PRLR heterodimer expression on the cell surface mediates re-
ceptor and JAK2 clustering such that autophosphorylation and
activation is possible without PRL ligand engagement.
Anti-tumor agents targeting the PRLR pathway are being
investigated for patients with ERa+ breast cancer. For example,
LFA102, an anti-PRLR antibody, blocks PRLRpathway activation
byeither inhibitingPRLRdimerizationor locking thePRLRdimer in
an inactive conformation without affecting PRL ligand binding
(Damiano et al., 2013). Because truncated PRLR expression is
preferentially increased in ERa+ breast cancer and FL/T PRLR
heterodimers display constitutive activation, as shown in our cur-
rent study, it would be of interest to examine whether LFA102 is
able to block heterodimerization of full-length and truncated
PRLR in future studies. Unfortunately, LFA102 failed to show anti-
tumorefficacy ina recentphase1clinical trial formetastaticbreast
cancer (Agarwal et al., 2016). Direct inhibition of JAK2 using small
molecule inhibitors will also be worthy of investigation in breast
cancers with PRLR activation. Future studies should also aim to
clarify the biological outcome of signaling crosstalk between the
FL/T PRLR heterodimers and the estrogen receptor pathway,
because combination therapy targeting both pathways may be
beneficial. In summary, our findings provide a mechanism
whereby ERa+ luminal breast cancer is initiated and maintained
and pose hypotheses of translational and clinical significance in
the treatmentof thismost commonhumanbreast cancersubtype.
EXPERIMENTAL PROCEDURES
Mice
Stat1/ mammary gland adenocarcinomas have been previously character-
ized in our laboratory (Chan et al., 2012, 2014; Shankaran et al., 2001). Wild-
type (WT) 129S6/SvEv and Stat1tm1Rds/tm1Rds (Stat1/) mice were purchased
from Taconic Farms. Stat1/ mammary tumors of approximately 10 mm in
diameter were harvested from 10–18-month-old retired breeders. Tumor-
free Stat1/ mice about 8 months of age were used as tumor-free controls.
To obtain ovarian hormone-independent mammary tumors, ovaries were sur-
gically removed from primary tumor-bearing mice as previously reported
(Chan et al., 2014). If tumors did not respond to estrogen-deprivation and
grew progressively, tumors were harvested. Tails from both tumor-free and tu-
mor-bearing Stat1/mice were also harvested as normal controls. All animal
experiments were carried out according to the guidelines of the American
Association for Laboratory Animal Science under a protocol approved by
the Animal Studies Committees and performed in Association for Assessment
and Accreditation of Laboratory Animal Care International (AAALAC)-ac-
credited specific pathogen-free facilities at Washington University School of
Medicine in St. Louis.
Cell Cultures
The SSM1, SSM2, and SSM3 Stat1/ mammary tumor cell lines were
cultured as previously described (Chan et al., 2012).
Sample Acquisition
Genomic DNAs were purified from tumor-free mammary glands, whole
tumors, or tails using QIAGEN DNeasy Blood & Tissue kit according to the
manufacturer’s instructions (QIAGEN). Fifty-two samples were whole genome
sequenced for discovery purposes, and an additional 54 samples wereCell Reports 17, 249–260, September 27, 2016 257
sequenced using the Sanger protocol for targeted validation and extension of
the Prlr findings (Figures 1 and S2). The discovery set included 14 primary
Stat1/ mammary tumors, 5 ovarian hormone (OH)-independent tumors,
and the 3 cell lines (SSM1, SSM2, and SSM3) for a total of 22 tumors from
20 individual mice (2 mice had 2 tumors each). An additional 10 WT and 5 tu-
mor-free Stat1/ mammary glands from 13 additional mice were also
sequenced as controls (2 mice had both tumor-bearing and tumor-free mam-
mary glands). From the Stat1/ mice, 15 tails were sequenced as matched
normal samples for 12 primary tumors, 2 OH-independent tumors, and 5 tu-
mor-free mammary glands. For 2 primary tumors, 3 OH-independent tumors,
3 cell lines, and 10 wild-type mammary glands without matched tails, a pooled
sample of 2 unmatched normal tails was used as reference for somatic variant
calling (see Table S7 for extensive details of all samples).
Whole Genome Sequencing
The yield and integrity of native genomic DNA was verified by a PicoGreen
assay to determinemass (Invitrogen). Small insert dual indexed Illumina paired
end libraries were constructed with the KAPA LTP sample prep kits according
to themanufacturer’s recommendations (KAPABiosystems) with a few excep-
tions (Supplemental Experimental Procedures). Each genomewas loaded on a
HiSeq2000 version 3 flow cell according to the manufacturer’s recommenda-
tions (Illumina). 23 101 bp read pairs were generated for each sample, yielding
an average of 37.13 sequence coverage for the tumor genomes and 27.23
sequence coverage for the normal genomes (Table S8).
Reference Alignment and Somatic Variant Detection
The Genome Modeling System, an integrated analysis information manage-
ment system, was used for preliminary analysis of sequence data as previously
described (Supplemental Experimental Procedures) (Griffith et al., 2015).
Alignment was performed against the mouse reference genome (mm9), and
variants were annotated with our custom annotator against Ensembl (version
67). Further filtering of SNVs and indels was performed to exclude (1) random,
mitochondrial (MT), and Y contig events; (2) germline events defined as greater
than 5% variant allele frequency (VAF) in the normal sample; (3) events with
greater than 500 reads at the site; (4) variants from the Sanger Mouse Ge-
nomes Project (v2); and (5) variants that appear in 2 or more of the 10WGS da-
tasets from mammary tissue samples obtained from wild-type mice. These
represent likely systematic artifacts of our alignment and calling pipelines.
Further manual review of all SNVs, indels, and CNVswas performed in the Inte-
grative Genome Viewer (IGV) to eliminate false positives arising from likely read
mapping artifacts. Finally, analysis was performed on all reviewed and somatic
variants (Table S1) to identify the recurrent (Table S2) and significantly mutated
genes (Table S3) for SNVs and indels. Significantly mutated genes were deter-
mined using the Mutational Significance in Cancer (MuSiC) pipeline (version
0.4), including non-coding mutations in the background mutation rate calcula-
tion (Dees et al., 2012). Reviewed CNV events are also summarized in Table
S9. Genomic visualizations (Figure S1A) were created with the GenVisR Bio-
conductor package (Skidmore et al., 2016).
Validation and Extension Sequencing of Prlr by Sanger and MiSeq
Based on the region in which truncating Prlr mutations were observed in the
discovery set (chr15:10258139–10258195;mm9), two sets of primers were de-
signed to encompass this region with approximately 50 or 100 bp additional
flanking sequence on each side, respectively (Table S10; Supplemental Exper-
imental Procedures). Primers were tailed (p1k/m13 reverse) and ordered from
Integrated DNA Technologies (IDT). Amplification was performed in a Bio-Rad
thermocycler (Bio-Rad Laboratories). A Lonza flash gel was run to confirm
product. Sequencing reactions were performed and loaded on a 3730 DNA
analyzer (Life Technologies). Bases were called from sequence trace files us-
ing phred and then assembled against a reference scaffold of the amplicon
sequence using phrap (Ewing and Green, 1998; Ewing et al., 1998). Sequence
variants were identified by manual review of assemblies and sequence traces
in Consed (Gordon et al., 1998). We performed Sanger sequencing as
described above on the original 22 tumor samples to validate Prlr variants
that were called fromWGS data and to extend the Prlr findings to 10 additional
tumors and 35 non-tumor samples (Figures 1 and S2). For two tumors in the
original discovery set, additional FFPE samples were obtained and sequenced258 Cell Reports 17, 249–260, September 27, 2016on a MiSeq Illumina instrument using products of the same PCR protocol
described above. Finally we sequenced an additional 9 FFPE samples by
MiSeq, to evaluate the presence of PRLR mutations in DCIS tissues.
Review of PRLR Sequence Data from TCGA Human Breast Cancers
The mutated region of mouse Prlr (chr15:10258139–10258195; mm9) and the
flanking 50 base pairs on each side were aligned to the human reference
genome using BLAST to identify the homologous region of PRLR in the human
genome (chr5:35066045–35066101; hg19). This region in human PRLR was
then extended to include the entirety of the affected ‘‘long’’ exon of PRLR (Fig-
ure S6) as well as the upstream-most exon-intron boundary and exon to iden-
tify a target region of interest (chr5:35065191–35068387; hg19) for manual re-
view in human sequence data using IGV. Manual review focused on identifying
truncatingmutations or deletions of the long exon. For amutation to be consid-
ered credible, at least a 3% tumor VAF was required. A total of 991 tumor and
normal pairs of exome sequence data were investigated from the breast TCGA
project, including 501 luminal A, 198 luminal B, 171 basal, 77 Her2, 31 normal-
like, and 13 of unknown subtype (Cancer Genome Atlas Network, 2012).
Exome Analysis of TCGA Human Breast Cancers
Genes with somatic mutations for mouse data (Table S1, n = 22) and human
luminal breast cancers from TCGA (n = 699) were compared (Figure S1). Within
the comparison, mutation types were restricted to nonsynonymous coding
and RNA mutations to ensure results were directly comparable. Using bio-
maRt, Homo sapiens and Mus musculus ensembl IDs were annotated with
orthologs from the other species. Genes without an ortholog with a one to
one mapping were excluded from the analysis. Instances in which a sample
had more than one mutation in the same gene were treated as having a single
mutation.
RNA-Seq Analysis of TCGA Human Breast Cancers
Breast cancer RNA-seq level 3 data corresponding to 10/10/2013 from the
firehose pipeline (http://gdac.broadinstitute.org) were obtained from the
TCGA data portal. A total of 775 breast tumor samples were represented
with 376 luminal A, 181 luminal B, 131 basal, 65 Her2, and 22 normal-like sub-
type. Read counts per kb permillion (RPKM) valueswere calculated as number
ofmapped reads / (transcript length in bp / 1,000) / (total reads / 1,000,000) and
used to define STAT1 and PRLR gene expression levels. Tumor samples
(excluding normal-like) were divided into tertiles to define low, intermediate,
and high STAT1 expression groups (Figure 4). Junction fragments per million
(JPM) values were defined as the raw counts for each junction, divided by
the sum of all junctions, and multiplied by one million. PRLR full-length and
truncated (short) isoform expression were estimated from the JPM values of
FL and T isoform-specific junctions as follows (Figure S6):
Full­lengthðFLÞ= Junction 9B ðJunction 3A + Junction 10AÞ
TruncatedðTÞ= Junction 10A + Junction 9A + Junction 7A + Junction 3A
The ratio of PRLR isoform expression was defined as the log2 value of FL
expression divided by T expression. As illustrated in Figure S6, the short hu-
man PRLR isoforms are generated by alternative splicing and will be defined
as ‘‘truncated’’ for clarification purposes. It should also be noted that human
FL and intermediate isoform expression were grouped as ‘‘full-length’’
because it is unachievable to extract FL expression alone using junction
data from TCGA.
Immunoprecipitation and Western Blotting Analysis
SSM1, SSM2, and SSM3 cells were lysed using complete RIPA buffer, and
PRLR was immunoprecipitated using anti-mPRLR (clone 5A12) as previously
described (Chan et al., 2014). Membrane was blotted with biotinylated anti-
mPRLR and streptavidin-anti-hamster-IR800 and scanned using the Li-Cor
Odyssey detection system.
Immunohistochemistry
Immunohistochemical analyses of STAT3 and STAT5 onStat1/DCIS lesions
were performed as described in a previous study (Chan et al., 2014).
Expression of Full-Length and Truncated Prlr
Full-length or truncated Prlr were cloned into pLVX-Het-1 or pLVX-Het-2,
respectively (Clontech). The shortest predicted variant of mutated Prlr (resi-
dues 1 to 317) was used as the T Prlr isoform, as shown in Figure S4.
Stat1/ murine embryonic fibroblasts were transduced with lentivirus ex-
pressing either FL or T Prlr alone or both FL and T Prlr together. In cells
expressing both FL and T Prlr, FL Prlr was transduced first. PRLR-positive
cells were sorted by flow cytometry using the anti-PRLR Ab clone 5A12,
and sorted cells were subsequently transduced with T Prlr. Because MEFs
did not express sufficient JAK2 to mediate signaling, Stat1/ MEFs were
also transduced with mouse JAK2.IRES.GFP and sorted for GFP-positive
cells.
Flow Cytometry
Cell surface expression of PRLR in Stat1/ MEFs was confirmed using
a biotinylated monoclonal antibody against murine PRLR (clone 5A12)
(Chan et al., 2014) and streptavidin-PE (SA-PE, eBioscience). To examine
basal activation of STAT3 and STAT5, MEFs were serum-deprived in
0.05% FBS for 16 hr before analysis. Cells were fixed and permeabilized
according to manufacturer’s protocol (BD Biosciences). Tyrosine phos-
phorylation of STAT3 and STAT5a/5b was detected using antibodies
specific for the phosphorylated forms of each STAT (Cell Signaling).
Monoclonal rabbit immunoglobulin G (IgG) was used as isotype control for
gating.
Soft Agar Assay
Single cell suspensions of 20,000 or 50,000 Stat1/ MEFs expressing FL,
truncated PRLR, or both were mixed in 0.3% noble agar in DMEM and plated
on top of 0.6% noble agar. Each condition was plated in triplicate in p60
dishes. The number of colonies in each dish was counted after 3 weeks using
a Scan 100 colony counter.
Analysis of Tumorigenicity in Nude Mice
Female NCr nude mice (Taconic) were implanted with 13 106 of immortalized
Stat1/ MEFs expressing JAK2 alone, FL PRLR/JAK2, T PRLR/JAK2, FL/T
PRLR/JAK2, or KRAS in 100 mL vehicle. Tumor diameter was measured twice
weekly. Animals were censored when progressively growing palpable tumors
of at least 2 mm were detected. On day 63, all remaining mice were sacrificed
and evaluated for evidence of tumors prior to considering animals to be tumor-
free.
Statistical Analyses
Wilcox rank sum test with continuity correction was performed to test for an
association between PRLR isoform ratio and STAT expression group and
plotted using geom_boxplot and geom_violin of the ggplot2 package
(v0.9.2.1) (Figure 4). Unpaired t test was used to determine the statistical
significance between control and experimental groups in the soft agar
assay (Figure 3B). All tests were two-sided and a p value% 0.05 was consid-
ered significant. Fisher’s exact test was used to compare tumor formation
in each group of nude mice implanted with Stat1/ MEFs to the FL/T ex-
pressing group (Figure 3C). Kaplan-Meier survival analysis was performed
using log-rank test. All statistical analysis was performed in R or GraphPad
Prism.
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